The endocannabinoid (eCB) system has been implicated in a variety of physiological functions due to abundant expression of its receptors and endogenous ligands in the central nervous system. Substantial progress has been made in understanding how the eCB system influences the brain norepinephrine (NE) system, an important neurochemical target in the continued development of new therapies for stress-induced psychiatric disorders. We, and others, have characterized the neuroanatomical, biochemical and pharmacological effects of cannabinoid receptor modulation on brain noradrenergic circuitry and defined how molecular elements of the eCB system are positioned to directly impact the locus coeruleus (LC)-prefrontal cortex pathway, a neural circuit well recognized for contributing to symptoms of hyperarousal, a key pathophysiological feature of stress-related disorders. We also described molecular and electrophysiological properties of LC noradrenergic neurons and NE release in the medial prefrontal cortex under conditions of cannabinoid type 1 receptor deletion. Finally, we identified how stress influences cannabinoid modulation of the coeruleo-cortical pathway. A number of significant findings emerged from these studies that will be summarized in the present review and have important implications for clinical studies targeting the eCB system in the treatment of stress-induced psychiatric disorders.
Endocannabinoids, stress signaling, and the locus coeruleus-norepinephrine system
Creators
Ryan R. Wyrofsky - Drexel University
Beverly A. S. Reyes - Drexel University
Xiao-Yan Zhang - Children's Hospital of Philadelphia
Seema Bhatnagar - Children's Hospital of Philadelphia
Lynn G. Kirby - Temple University
Elisabeth J. Van Bockstaele - Drexel University
Publication Details
Neurobiology of stress, v 11, pp 100176-100176
Publisher
Elsevier
Number of pages
13
Grant note
R01MH093981 / NATIONAL INSTITUTE OF MENTAL HEALTH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)
P30DA013429 / NATIONAL INSTITUTE ON DRUG ABUSE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); European Commission
DA020129; P30 DA013429; MH093981 / National Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
Resource Type
Journal article
Language
English
Academic Unit
Pharmacology and Physiology
Web of Science ID
WOS:000500476200012
Scopus ID
2-s2.0-85067282261
Other Identifier
991019185108404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool: